In addition, Resolvins (69), PNU-282987 (a selective α7-nAChR agonist) (70) and infliximab (TNF-α antagonist) (46) are also reported to reduce T-cell invasion in AAA, thus inhibiting the progression of AAA. Here, CHRNA7 is linked to triple-A syndrome.